Interview: Impact of JCA and Project Orbis on the European revenue potential of an oncology product
-
Claudio Valenti, MA
A conversation with Claudio Valenti
In anticipation of the 2025 ISPOR meeting, we had the opportunity to speak with Claudio Valenti, Senior Manager Market Access, to discuss his poster “Impact of JCA and Project Orbis on the European Revenue Potential of an Oncology Product.” Valenti’s research examines the impact of Joint Clinical Assessment (JCA) and Project Orbis on the revenue potential of oncology products, highlighting that these initiatives can lead to higher and faster revenues for biopharma.
*Available in English only
What inspired this research?
The goal of our research was to determine whether JCA and Project Orbis present an opportunity for pharmaceutical companies and to quantify this potential in terms of revenues for a hypothetical new oncology treatment.
Was there a hypothesis that the research confirmed?
What are the key takeaways from your research?
JCA and Project Orbis offer pharmaceutical manufacturers the opportunity to achieve higher revenues within a shorter time horizon. The impact of international reference pricing (IRP) on prices appears to be low to minimal. Although faster price erosion may occur due to earlier availability in some low-price European markets following JCA and Project Orbis, this effect is expected to be outweighed by a faster uptake in volume.
In our base-case scenario, JCA and Project Orbis could have represented an 11 percent revenue increase over five years compared to previous models. The projected impact ranged from +3 percent in our worst-case scenario to +14 percent in our best-case scenario.
Was there anything in the research that was surprising, that you didn't expect, that you found out?
What are the next steps from this research?
Moving forward, it will be essential to focus on estimating the net price of new pharmaceutical products, providing further insight into the real revenue impact of JCA and Project Orbis.
Citations relevant to the content described herein are provided in the poster mentioned here. Readers should review all available information related to the topics mentioned herein and rely on their own experience and expertise in making decisions related thereto.
Connect with our team
